Valneva SE Sponsored ADR (NASDAQ:VALN) Receives $11.97 Consensus Target Price from Brokerages

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have earned a consensus rating of “Hold” from the five analysts that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $11.9750.

A number of brokerages have commented on VALN. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Guggenheim set a $11.00 price objective on shares of Valneva in a research note on Thursday, April 16th. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, The Goldman Sachs Group downgraded Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a research report on Wednesday, April 22nd.

Institutional Trading of Valneva

A number of large investors have recently modified their holdings of VALN. China Universal Asset Management Co. Ltd. purchased a new stake in Valneva in the fourth quarter valued at approximately $44,000. VSM Wealth Advisory LLC raised its position in shares of Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Valneva during the 3rd quarter worth $124,000. XTX Topco Ltd bought a new stake in shares of Valneva during the 4th quarter worth $94,000. Finally, Marex Group plc purchased a new position in Valneva in the second quarter worth $64,000. Institutional investors own 11.39% of the company’s stock.

Valneva Stock Performance

Shares of VALN stock opened at $5.05 on Monday. The firm has a 50 day moving average of $5.55 and a 200-day moving average of $7.65. The company has a market cap of $479.19 million, a price-to-earnings ratio of -2.70 and a beta of 1.77. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. Valneva has a 52 week low of $5.04 and a 52 week high of $12.25.

Valneva (NASDAQ:VALN) last released its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. The company had revenue of $35.77 million for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. On average, equities analysts forecast that Valneva will post -1 earnings per share for the current year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.